Orexigen Therapeutics News

HotStockProfits.com Releases New Technical Trading Reports on Republic Services, Inc.

May 11 -- Arena Pharmaceuticals Inc. jumped the most ever after the company's weight-loss pill gained the backing of an advisory panel, putting two obesity drugs in line for U.S. approval almost two years after regulators rejected them as too risky.

The top after-market NASDAQ gainers Thursday were: Arena Pharmaceuticals, Inc., Brooks Automation, Inc., Orexigen Therapeutics, Inc., Mindspeed Technologies, Inc.

Arena Pharmaceuticals Inc. won the backing of a U.S advisory panel for a weight-loss medicine competing to become the first obesity pill approved in 13 years.

SAN DIEGO, May 9, 2012 /PRNewswire/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2012.

Therapeutics, Inc. today announced that management will be presenting at two upcoming investor conferences.

Orexigen Therapeutics, Inc. Schedules May 9, 2012 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2012 /PRNewswire/ -- OrexigenA Therapeutics, Inc.

Arena Pharmaceuticals shares surged strongly on Friday, up 34% intra-day to $2.89 from Thursday closing price of $2.15, settling at the end of the day at $2.62 for a gain of 22%. The company is a biotech developer of oral drugs for cardiovascular, central nervous system, inflammatory, and metabolic diseases.